Pharma chooses to 'Waiver' rather than test new cancer drugs in children
This article was originally published in Scrip
The Institute of Cancer Research has made available data highlighting which oncology drugs approved in the EU recently have a relevant mechanism of action in a childhood cancer but companies were able to 'opt out' of submitting pediatric investigation plans (PIPs) for.
You may also be interested in...
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.